Boston, MA – On January 24, 2018, Human Metabolome Technologies, Inc. (hereinafter referred to as HMT, Head office: Tsuruoka City, Yamagata Prefecture, President: Ryuji Kanno,) have announced that a biomarker for the diagnosis of Major Depression Disorder (MDD), which is being developed collaboratively with the Medical Corporation Association Gyo-ki kai, Kawamura general clinic (Tokyo, Japan, Representative: Noriyuki Kawamura, MD), has been published in Psychiatry and Clinical Neurosciences.